What is the role of PARP inhibitors in treating Ovarian Cancer

PARP Inhibitors in Ovarian Cancer Treatment

PARP inhibitors have become an important part of ovarian cancer treatment, particularly for patients with specific genetic mutations. Let me explain how they work and when they're used.

How PARP Inhibitors Work

PARP stands for poly(ADP-ribose) polymerase — an enzyme that acts like a "repair crew" for damaged DNA in cells. PARP inhibitors are drugs that block this repair enzyme, preventing cancer cells from fixing DNA damage. This is especially effective in ovarian cancer cells that already have faulty DNA repair systems.

The key insight: Cancer cells with BRCA1/2 mutations (inherited genetic changes) or other DNA repair defects are particularly vulnerable to PARP inhibitors because they can't fix the damage that accumulates when PARP is blocked. Normal cells, which have working backup repair systems, are mostly spared.

Two Main Treatment Settings

According to the NCCN Guidelines for Ovarian Cancer, PARP inhibitors are used in two different situations:

1. Maintenance Therapy After First-Line Treatment

After you complete initial chemotherapy for newly diagnosed ovarian cancer, PARP inhibitors can be used as "maintenance therapy" — ongoing treatment to prevent or delay recurrence.

For patients with BRCA1/2 mutations:

• Olaparib (single agent) is a Category 1 recommendation — meaning it's strongly supported by evidence
• In the SOLO-1 trial, patients taking olaparib had a 70% lower risk of progression or death compared to placebo
• Median progression-free survival (time before cancer returns) was not reached after 41 months of follow-up with olaparib, compared to 13.8 months with placebo

For patients without BRCA mutations but with HRD (homologous recombination deficiency):

• Niraparib and rucaparib are options
• Benefits are smaller but still meaningful — roughly 40-60% reduction in progression risk depending on HRD status

Combination approaches:

• Olaparib + bevacizumab (a different type of cancer drug) is recommended for patients who received bevacizumab during their initial chemotherapy
• The PAOLA-1 trial showed this combination reduced progression risk by 41% overall, with even greater benefit (69% reduction) in BRCA-mutated patients

2. Treatment for Recurrent Ovarian Cancer

If your cancer returns after initial treatment, PARP inhibitors can be used again, particularly if:

• Your cancer is "platinum-sensitive" (responds well to platinum-based chemotherapy)
• You have a BRCA mutation
• You haven't previously progressed on a PARP inhibitor

Important Considerations

Who benefits most: According to NCCN Guidelines, the strongest evidence supports PARP inhibitor use in patients with:

• High-grade serous ovarian cancer
• Grade 2/3 endometrioid ovarian cancer
• BRCA1/2 mutations (germline or somatic)
• HRD-positive tumors (if no BRCA mutation)

Testing is essential: Your oncologist should recommend genetic testing to determine:

• Whether you have a BRCA1/2 mutation
• Your HRD (homologous recombination deficiency) status if you don't have a BRCA mutation

This testing guides which PARP inhibitor approach makes sense for your specific situation.

Duration of treatment:

• Maintenance therapy typically continues until disease progression or unacceptable side effects
• Treatment duration varies: olaparib may continue up to 2 years, niraparib up to 3 years, depending on the regimen

Questions to Ask Your Oncologist

1. Do I have a BRCA1/2 mutation or HRD-positive tumor? (This determines if PARP inhibitors are recommended for me)
2. Which PARP inhibitor do you recommend for my specific situation — and why?
3. How long would I take this medication, and how will we monitor if it's working?
4. What side effects should I watch for, and how are they managed?
5. If my cancer progresses on this PARP inhibitor, what are the next treatment options?

Key Takeaway

PARP inhibitors represent a significant advance in ovarian cancer treatment, particularly for patients with BRCA mutations or HRD-positive tumors. According to the NCCN Guidelines, they can substantially delay cancer recurrence and are now standard options for maintenance therapy after initial treatment. However, the decision to use them depends on your specific genetic profile and cancer characteristics — which is why genetic testing and discussion with your oncology team are so important.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.